Skip to main content
. Author manuscript; available in PMC: 2007 Aug 23.
Published in final edited form as: Curr Opin Oncol. 1999 Jan;11(1):50–57. doi: 10.1097/00001622-199901000-00012

Table 2.

Characteristics of the 13 patients with metastatic malignant melanoma who had objective responses to modified gp100 peptide (g209-2M) plus IL-2CR—complete remission; IL—interleukin; PR—partial response. Adapted from Rosenberg et al.[48••], with permission

Patient Age, yr/Sex Tumor site Type Response duration, mo
a 48/M Lung CR 6
b 51/M Lung, subcutaneous PR 6
c 44/M Lymph node, lung, subcutaneous, cutaneous PR 2+
d 45/F Lymph node, bone, subcutaneous PR 4
e 42/F Cutaneous, subcutaneous, liver PR 7+
f 41/F Lung PR 5+
g 39/M Lung PR 6
h 22/F Lung hilum PR 5
i 48/M Cutaneous PR 6
j 43/M Subcutaneous PR 5+
k 42/F Lung, lymph node, liver, brain PR 2
l 47/F Lung, lymph node PR 5+
m 59/M Subcutaneous PR 3+

CR–complete remission; IL-interleukin; PR–partial response.

Adapted from Rosenberg et al. [48 ••], with permission.